n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)
Stocks to Watch: Disney, Sirius

Stocks to Watch: Disney, Sirius

Sirius XM Radio and Walt Disney are among companies scheduled to post quarterly results on Tuesday.

Market Preview: A Cautious Advance

Market Preview: A Cautious Advance

Stocks have roared back in the past few weeks with defensive sectors leading the way but that's not the whole story.

Elan Announces Johnson & Johnson Release Of Discontinuation Of Phase 3 Development Of Bapineuzumab Intravenous (IV) In Mild To Moderate Alzheimer’s Disease

Elan Announces Johnson & Johnson Release Of Discontinuation Of Phase 3 Development Of Bapineuzumab Intravenous (IV) In Mild To Moderate Alzheimer’s Disease

Elan Corporation, plc (NYSE:ELN) announced today that Johnson & Johnson has issued a press release regarding the discontinuation of Phase 3 development of bapineuzumab IV in mild to moderate Alzheimer’s.

Elan Management Discusses Q2 2012 Results - Earnings Call Transcript

Elan Management Discusses Q2 2012 Results - Earnings Call Transcript

Elan Management Discusses Q2 2012 Results - Earnings Call Transcript

Elan Reports Second Quarter And First Half 2012 Financial Results

Elan Reports Second Quarter And First Half 2012 Financial Results

Elan Corporation, plc today reported its second quarter and first half 2012 financial results.

Are Elan, Pfizer, Lilly and J&J Buys After a Failed Drug Test?

Are Elan, Pfizer, Lilly and J&J Buys After a Failed Drug Test?

Shares are down now but they could be worth buying later in the week.

Elan Announces Pfizer’s Release Of A Top-Line Result In First Of Four Bapineuzumab Phase 3 Trials

Elan Announces Pfizer’s Release Of A Top-Line Result In First Of Four Bapineuzumab Phase 3 Trials

Elan Corporation, plc (NYSE:ELN) announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.

Pfizer, J&J, Elan Alzheimer's Drug Fails

Pfizer, J&J, Elan Alzheimer's Drug Fails

The first of four phase III trials of bapineuzumab is a failure, Pfizer says.

Elan Announces Webcast Of Second Quarter 2012 Financial Results

Elan Announces Webcast Of Second Quarter 2012 Financial Results

Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Wednesday, July 25, 2012 at 8:30 a.

Elan-UCD Endowment Honours Irish Business Leaders And Boosts Ireland’s Capacity In The 'Business Of Biotechnology'

Elan-UCD Endowment Honours Irish Business Leaders And Boosts Ireland’s Capacity In The 'Business Of Biotechnology'

University College Dublin (UCD) and Elan Corporation plc, (NYSE: ELN) today announced two scholarships and an annual lecture series at University College Dublin (UCD) in the 'Business of Biotechnology' named in honour ...

Alkermes Needs to Build on Drug Delivery Success

Alkermes Needs to Build on Drug Delivery Success

An undervalued stock could move higher if Alkermes continues to grow through acquisitions.

Elan To Present At Jefferies 2012 Global Healthcare Conference

Elan To Present At Jefferies 2012 Global Healthcare Conference

Elan Corporation, plc (NYSE: ELN) announced today that it will present at the Jefferies 2012 Global Healthcare Conference on Monday, June 4th at 9:30am Eastern Daylight Time (EDT), 2:30pm British Summer Time (BST).

22 Biopharma Stocks With Breakout Potential in 2012

22 Biopharma Stocks With Breakout Potential in 2012

TheStreet's Adam Feuerstein has compiled a list of drugs with crucial, stock-moving clinical trial catalysts for the remainder of 2012.

New Analysis Of Risk Stratification For TYSABRI® Published In New England Journal Of Medicine

New Analysis Of Risk Stratification For TYSABRI® Published In New England Journal Of Medicine

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced that the New England Journal of Medicine published research from the companies’ global risk management program that...

A Health Care Fortnight for the Record Books

A Health Care Fortnight for the Record Books

Health care investor Nate Sadeghi says Pfizer is holding back bad news on its Alzheimer's drug, tells Human Genome to sell to Glaxo and likes Vertex and Gilead Sciences.

Elan Reports First Quarter 2012 Financial Results

Elan Reports First Quarter 2012 Financial Results

Elan Corporation, plc, today reported its first quarter 2012 financial results.

Elan Announces Webcast Of First Quarter 2012 Financial Results

Elan Announces Webcast Of First Quarter 2012 Financial Results

Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Thursday, April 26, 2012 at 8:30 a.

On Nowruz, Reviewing Drug Stock Picks

On Nowruz, Reviewing Drug Stock Picks

TheStreet's biotech contributor Nathan Sadeghi-Nejad looks back at his hits and misses with Amylin, Elan, Gilead Sciences, Onyx and Verastem.

Elan's Alzheimer's-Fueled Run Means Investors Are Forgetting the Past

Elan's Alzheimer's-Fueled Run Means Investors Are Forgetting the Past

Remembering the failed back story of Elan's Alzheimer's drug bapineuzumab as phase III trial results loom.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade higher from current levels.

Elan Raises $381 Million In Sale Of 76% Of Alkermes Holding

Elan Raises $381 Million In Sale Of 76% Of Alkermes Holding

Elan Corporation, plc (NYSE: ELN) today raised approximately $381 million in net proceeds from the sale of 76% (24.

Elan Chairman Provides Update On CEO Succession

Elan Chairman Provides Update On CEO Succession

The Chairman of Elan (NYSE:ELN), Mr. Robert Ingram today provided an update on CEO succession: “On June 3, 2010, Elan communicated that, as part of its prudent executive succession management process,...

The Case for Shorting Elan Into Upcoming Alzheimer's Trial Results

The Case for Shorting Elan Into Upcoming Alzheimer's Trial Results

The amyloid beta hypothesis doesn't explain Alzheimer's, which leaves Elan and its partners in trouble.

Elan Reports Fourth Quarter And Full-Year 2011 Financial Results

Elan Reports Fourth Quarter And Full-Year 2011 Financial Results

Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.

Elan To Present At The Leerink Swann 2012 Global Healthcare Conference

Elan To Present At The Leerink Swann 2012 Global Healthcare Conference

Elan Corporation, plc (NYSE:ELN) announced today that it will present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday February 15, 2012 at 2.

ASCEND Study To Evaluate The Effectiveness Of TYSABRI® (natalizumab) As A Treatment For Secondary-Progressive Multiple Sclerosis

ASCEND Study To Evaluate The Effectiveness Of TYSABRI® (natalizumab) As A Treatment For Secondary-Progressive Multiple Sclerosis

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for...

FDA Updates TYSABRI® (natalizumab) Label To Include Anti-JC Virus Antibody Status As A PML Risk Factor

FDA Updates TYSABRI® (natalizumab) Label To Include Anti-JC Virus Antibody Status As A PML Risk Factor

Today Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that the U.

Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data

Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data

Medivation puts the Alzheimer's drug Dimebon on the shelf and will now focus solely on its promising prostate cancer drug.

7 Relative Strength Stocks for 2012

7 Relative Strength Stocks for 2012

These top S&P names of the S&P rank high for outperformance.

7 Stocks Hitting New 52-Week Highs

7 Stocks Hitting New 52-Week Highs

When a stock is hitting new 52-week highs, it often means that the uptrend is very strong and the buyers are in full control.